Aitiologic is a precision-medicine startup based in Vienna that develops liquid biopsy platforms, including the aitios platform and aitios NIPPT. The company focuses on advanced molecular diagnostics to support personalized healthcare.
Subscribe to see Aitiologic’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Aitiologic is a healthcare company headquartered in Austria. Its most recent funding round, Seed, raised $7M in September 2026. Xcout tracks 4 named people at Aitiologic, including Rebecca Ertl (chief medical officer).
As of 16 November 2026. Source: Xcout Intel.
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $7M | 5 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Aitiologic's closest competitors — see the full list of competitors and alternatives →
Oncoliq is an Argentinian startup based in Buenos Aires that combines cutting-edge AI with molecular biology to develop an early cancer detection screening method using a liquid biopsy blood test.
EarlyDiagnostics, also known as EarlyDx, is a clinical-stage precision diagnostics company that develops non-invasive liquid biopsy technologies and genomics platforms for early cancer detection.
Celsee Diagnostics is a company operating in the rare disease diagnostics and liquid biopsy market. Based in Maryland, the company is involved in developing and assessing advanced healthcare technologies for cancer and genomic detection.
SAGA Diagnostics is a personalized cancer medicine and molecular diagnostics company headquartered in Lund, Sweden, focused on ultrasensitive molecular genetic testing of circulating tumor DNA and disease monitoring.
FYR Bio is a biotechnology company that develops precision medicine tools and diagnostic solutions using extracellular vesicles to provide RNA and protein insights from blood. The company leverages AI-enabled multiomic insights to support disease observation, biomarker development, and clinical trials.
Amoy Dx is a diagnostic company dedicated to transforming cancer care by breaking barriers in precision oncology. The company develops specialized genomic tools and diagnostics products, such as the AmoyDx Essential NGS Panel used in clinical trials. It operates as a visionary enterprise within the precision medicine and diagnostics sector.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Aitiologic? Suggest a correction · Work at Aitiologic? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.